Bempikibart (ADX-914) is under development for the treatment of atopic dermatitis and alopecia areata. It is administered through subcutaneous route and acts by targeting interleukin-7 receptor (IL-7R ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

Q32 Bio has built its reputation on a diverse pipeline targeting inflammatory conditions, with a particular focus on two key assets: ADX-914 (bempikibart) and ADX-097. The company's strategic approach ...

Q32 Bio has built its reputation on a diverse pipeline targeting inflammatory conditions, with a particular focus on two key assets: ADX-914 (bempikibart) and ADX-097. The company's strategic ...

AI can spot patterns in the data from blood tests that can give an early warning of disease. AI is trained to spot warning signs in blood tests AI can spot patterns in the data from blood tests ...

US biotech Q32 Bio released Ph IIA trial results for its bempikibart for alopecia areata that were described as “messy,” sending the firm’s shares plunging 75%. Keros Therapeutics was another big ...

The revision follows Q32 Bio's recent disclosures concerning its clinical trials, particularly the mixed results for its drug candidate, bempikibart. Q32 Bio recently reported negative results for ...